Related Experiment Videos
Susceptibility in vitro of Nocardia species to antimicrobial agents
P M Southern1, A E Kutscher, R Ragsdale
1Department of Pathology, University of Texas Health Science Center at Dallas 75235-9072.
Abstract:
Fifty-four clinical isolates of Nocardia spp. were tested in vitro for susceptibility to several antimicrobial agents. Of these, 89% were susceptible to ciprofloxacin, 86% to imipenem, 85% to fusidic acid, and 71% to cefotaxime. Some of the agents may be suitable alternative or adjunctive drugs to sulfonamides and aminoglycosides for chemotherapy of Nocardial infections.
Insights
This study evaluated antimicrobial susceptibility in Nocardia clinical isolates. Ciprofloxacin, imipenem, and fusidic acid showed high efficacy, suggesting potential alternatives for Nocardial infections.
Area of Science:
- Microbiology
- Infectious Diseases
- Antimicrobial Resistance
Background:
- Nocardia species are opportunistic pathogens causing infections in immunocompromised individuals.
- Traditional chemotherapy for Nocardial infections often relies on sulfonamides and aminoglycosides.
- Emerging antimicrobial resistance necessitates exploring alternative treatment options.
Purpose of the Study:
- To determine the in vitro antimicrobial susceptibility patterns of clinical isolates of Nocardia spp.
- To identify potential alternative or adjunctive antimicrobial agents for Nocardial infections.
Main Methods:
- Fifty-four clinical isolates of Nocardia spp. were collected.
- In vitro susceptibility testing was performed against various antimicrobial agents.
Main Results:
- High susceptibility rates were observed for ciprofloxacin (89%), imipenem (86%), and fusidic acid (85%).
- Cefotaxime demonstrated susceptibility in 71% of isolates.
- Varied susceptibility profiles indicate the need for tailored treatment approaches.
Conclusions:
- Ciprofloxacin, imipenem, and fusidic acid are promising agents for Nocardial infections.
- These antimicrobials may serve as effective alternatives or adjuncts to current therapies.
- Further clinical studies are warranted to confirm the efficacy of these agents.